Easy Branches allows you to share your guest post within our network in any countries of the world to reach Global customers start sharing your stories today!

Easy Branches

34/17 Moo 3 Chao fah west Road, Phuket, Thailand, Phuket

Call: 076 367 766

info@easybranches.com

Videos CNBC

Gilead's Twice-Yearly Shot to Prevent HIV Succeeds in Late-Stage Trial

An anonymous reader shared this report from CNBC: Gilead's experimental twice-yearly medicine to prevent HIV was 100% effective in a late-stage trial, the company said Thursday. None of the roughly 2,000 women in the trial who received the lenacapav

By: Slashdot.org

Jun 23 2024
8
292 Views

Gilead's Twice-Yearly Shot to Prevent HIV Succeeds in Late-Stage Trial

An anonymous reader shared this report from CNBC:
Gilead's experimental twice-yearly medicine to prevent HIV was 100% effective in a late-stage trial, the company said Thursday. None of the roughly … [+1134 chars]

Gilead's Twice-Yearly Shot to Prevent HIV Succeeds in Late-Stage Trial

Related

Prince Constantijn of the Netherlands, a special envoy to Techleap startup accelerator, says Europe risks falling behind the US and China by over-regulating AI (Ryan Browne/CNBC)

Trump Media Stock (DJT) - CNBC's Concerns Are Serious

Crawler ohne Grenzen: Perplexity ignoriert robots.txt

OpenAI Adds Former NSA Chief To Its Board

Paramount and Skydance have reached an $8 billion merger deal, report says

Apple Intelligence: Apple auf der Suche nach Partnern in China

Novo Nordisk announces new $4.1 billion facility in North Carolina

Sam's Club is winning over Gen Z shoppers with convenience, and that could spell trouble for Costco

Sunday Night Futures

Elon Musk walks back controversial comments to advertisers

Microsoft: Entlassungen im Mixed-Reality-Bereich

The Samsung Galaxy Ring suddenly got a whole lot less appealing

Prince Constantijn of the Netherlands, a special envoy to Techleap startup accelerator, says Europe risks falling behind the US and China by over-regulating AI (Ryan Browne/CNBC)